PMV Pharmaceuticals (NASDAQ:PMVP) Posts Quarterly Earnings Results

PMV Pharmaceuticals (NASDAQ:PMVP) announced its quarterly earnings data on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06, FiscalAI reports.

PMV Pharmaceuticals Trading Up 7.2%

PMVP opened at $1.64 on Friday. The stock has a market cap of $87.26 million, a PE ratio of -1.10 and a beta of 1.27. The stock’s fifty day simple moving average is $1.20 and its 200 day simple moving average is $1.30. PMV Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.88.

Hedge Funds Weigh In On PMV Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. XTX Topco Ltd increased its position in PMV Pharmaceuticals by 144.3% during the 4th quarter. XTX Topco Ltd now owns 104,485 shares of the company’s stock worth $131,000 after buying an additional 61,723 shares during the period. Tang Capital Management LLC boosted its holdings in PMV Pharmaceuticals by 3.2% in the 4th quarter. Tang Capital Management LLC now owns 4,940,000 shares of the company’s stock valued at $6,175,000 after purchasing an additional 154,799 shares during the period. Bridgeway Capital Management LLC boosted its holdings in PMV Pharmaceuticals by 33.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 428,853 shares of the company’s stock valued at $536,000 after purchasing an additional 108,200 shares during the period. Public Employees Retirement System of Ohio grew its position in shares of PMV Pharmaceuticals by 349.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock worth $34,000 after purchasing an additional 21,334 shares in the last quarter. Finally, Squarepoint Ops LLC grew its position in shares of PMV Pharmaceuticals by 101.8% during the 4th quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock worth $33,000 after purchasing an additional 13,367 shares in the last quarter. Institutional investors own 90.20% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PMV Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $5.00.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.